Clinical Assessment, Genetics, and Treatment Approaches in Autism Spectrum Disorder (ASD)

被引:153
作者
Genovese, Ann [1 ]
Butler, Merlin G. [1 ]
机构
[1] Univ Kansas, Med Ctr, Dept Psychiat & Behav Sci, Kansas City, KS 66160 USA
关键词
autism; ASD; genetics; heterogeneity; syndromes; assessment; medications; treatment; causes; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; BEHAVIORAL SYMPTOMS; MITOCHONDRIAL-DNA; CHILDREN; RISPERIDONE; GENES; PHARMACOGENETICS; METAANALYSIS;
D O I
10.3390/ijms21134726
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Autism spectrum disorder (ASD) consists of a genetically heterogenous group of neurobehavioral disorders characterized by impairment in three behavioral domains including communication, social interaction, and stereotypic repetitive behaviors. ASD affects more than 1% of children in Western societies, with diagnoses on the rise due to improved recognition, screening, clinical assessment, and diagnostic testing. We reviewed the role of genetic and metabolic factors which contribute to the causation of ASD with the use of new genetic technology. Up to 40 percent of individuals with ASD are now diagnosed with genetic syndromes or have chromosomal abnormalities including small DNA deletions or duplications, single gene conditions, or gene variants and metabolic disturbances with mitochondrial dysfunction. Although the heritability estimate for ASD is between 70 and 90%, there is a lower molecular diagnostic yield than anticipated. A likely explanation may relate to multifactorial causation with etiological heterogeneity and hundreds of genes involved with a complex interplay between inheritance and environmental factors influenced by epigenetics and capabilities to identify causative genes and their variants for ASD. Behavioral and psychiatric correlates, diagnosis and genetic evaluation with testing are discussed along with psychiatric treatment approaches and pharmacogenetics for selection of medication to treat challenging behaviors or comorbidities commonly seen in ASD. We emphasize prioritizing treatment based on targeted symptoms for individuals with ASD, as treatment will vary from patient to patient based on diagnosis, comorbidities, causation, and symptom severity.
引用
收藏
页码:1 / 18
页数:18
相关论文
共 119 条
[1]   Advances in autism genetics: on the threshold of a new neurobiology [J].
Abrahams, Brett S. ;
Geschwind, Daniel H. .
NATURE REVIEWS GENETICS, 2008, 9 (05) :341-355
[2]   Psychopharmacological interventions in autism spectrum disorder [J].
Accordino, Robert E. ;
Kidd, Christen ;
Politte, Laura C. ;
Henry, Charles A. ;
McDougle, Christopher J. .
EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (07) :937-952
[3]  
Aiello R, 2014, AHRQ PUBLICATION
[4]  
Aman M. G., 1986, Aberrant Behavior Checklist: Manual
[5]  
Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266
[6]  
American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]
[7]  
[Anonymous], 2006, MMWR-MORBID MORTAL W, V58, P1, DOI DOI 10.1371/J0URNAL.P0NE.0124120
[8]   Management of Sleep Disorders in Children With Neurodevelopmental Disorders: A Review [J].
Blackmer, Allison Beck ;
Feinstein, James A. .
PHARMACOTHERAPY, 2016, 36 (01) :84-98
[9]   Trends in the Prevalence of Developmental Disabilities in US Children, 1997-2008 [J].
Boyle, Coleen A. ;
Boulet, Sheree ;
Schieve, Laura A. ;
Cohen, Robin A. ;
Blumberg, Stephen J. ;
Yeargin-Allsopp, Marshalyn ;
Visser, Susanna ;
Kogan, Michael D. .
PEDIATRICS, 2011, 127 (06) :1034-1042
[10]  
Butler Merlin G, 2018, J Ment Health Clin Psychol, V2, P17